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ABSTRACT
Objective: We conducted a study of minocycline to assess its safety, tolerability, and efficacy for
the treatment of HIV-associated cognitive impairment.
Methods: HIV-1-infected individuals with progressive neurocognitive decline were enrolled in a
double-blind, placebo-controlled study of minocycline. Participants were randomized to receive mino-
cycline 100 mg or matching placebo orally every 12 hours. The primary efficacy measure was change
in a neuropsychological test composite z score (NPZ-8) from baseline to week 24. Measures of safety
included the frequency of adverse events and changes over time in laboratory tests. After 50% of
participants completed the double-blind phase, an interim analysis of futility for the primary outcome mea-
sure was performed, and our Data and Safety Monitoring Board recommended early study termination.
Results: A total of 107 HIV-1-infected individuals with cognitive impairment were enrolled. The
minocycline group did not show improvement in the primary outcome measure (NPZ-8) (mean
24-week change  0.12) compared to placebo (mean 24-week change  0.17) (95% confidence
interval  [0.26, 0.39], p  0.70). There were few severe adverse events or laboratory abnor-
malities in either treatment group.
Conclusion: Minocycline was safe and well-tolerated in individuals with HIV-associated cognitive
impairment, but cognitive improvement was not observed.
Classification of evidence. This interventional study provides Class II evidence for the safety,
tolerability, and efficacy of minocycline for the treatment of HIV-associated cognitive impair-
ment. Neurology® 2011;77:1135–1142
GLOSSARY
ACTG  AIDS Clinical Trials Group; ADC  AIDS Dementia Complex; ALS  amyotrophic lateral sclerosis; CALCAP  California
Computerized Assessment Package; CES-D  Center for Epidemiologic Studies Depression Scale; HAART  highly active anti-
retroviral therapy; HAND  HIV-associated neurocognitive disorder; HVLT-R  Hopkins Verbal Learning Test Revised; MS 
multiple sclerosis; NPZ-8  neuropsychological z score; WAIS-R  Wechsler Adult Intelligence Scale–Revised.
Cognitive impairment continues to be an important manifestation of HIV-1 infection in
40%–50% of HIV-1 seropositive (HIV) individuals in the era of highly active antiretroviral
therapy (HAART).1 The use of HAART may improve cognitive performance2–4 but the treat-
ment response is frequently incomplete, or the antiretroviral drugs are unable to penetrate into
the CNS. An adjunctive therapy that interferes with the cascade of inflammatory events trig-
gered by the HIV virus within the CNS is likely to play an important role in the future
treatment of HIV-associated neurocognitive disorders (HAND).5
Minocycline has both anti-inflammatory and neuroprotective effects in in vitro models6 and
has been shown to affect cytokine production by monocytes and T lymphocytes,7 inhibit
microglia activation,8 reduce excessive matrix metalloproteinase activity,9 inhibit nitric oxide
synthesis,10 and inhibit apoptotic cell death.11–13 Minocycline offers a unique therapeutic strat-
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egy for HAND because it may also have a
direct effect in inhibiting HIV replication.14
In SIV encephalitis, an animal model for
HAND, minocycline has been linked to sup-
pressed activation of p38 MAP kinase. In this
model, minocycline-treated animals demon-
strated a reduction in the severity of SIV en-
cephalitis and lower levels of viral RNA in
both CSF and brain homogenates compared
with SIV-infected, untreated controls.
Minocycline-treated macaques also had lower
brain levels of activated p38 MAP kinase, a
proapoptotic neurodegenerative MAP kinase.
In addition, minocycline may also inhibit
both SIV and HIV replication in cultured pri-
mary macrophages14,15 and lymphocytes,
the predominant target cells productively in-
fected by the viruses. Viral replication (quan-
titation of SIV measured by p27 expression,
and HIV measured by p24 expression) was
suppressed in a dose-dependent fashion. Based
upon these preliminary data, we conducted a
phase II, randomized, double-blind, placebo-
controlled study of minocycline to assess the
safety, tolerability, and efficacy of minocy-
cline for the treatment of HIV-associated cog-
nitive impairment.
METHODS Recruitment/enrollment. From March 2007
to September 2009, 107 HIV individuals with cognitive im-
pairment and on a stable antiretroviral regimen for at least 16
weeks prior to study entry were enrolled across 16 US sites. The
number of individuals completing each study phase is shown in
the figure. Cognitive impairment was defined as performance
compared to age-, education-, and, where available, gender- and
race-matched controls at least 1.0 SD below on 3 or more inde-
pendent neuropsychological tests, or at least 2.0 SD on one test
and at least 1.0 SD on a second test at the screening visit. Nor-
mative values were obtained from HIV-negative neurologically
asymptomatic individuals from the Multicenter AIDS Cohort
Study.16 In addition to impaired performance at screening, pro-
gressive neurocognitive decline established by either objective or
subjective criteria was also a requirement for enrollment. Objec-
tive criteria were defined as a decline of at least 1.0 SD below on
2 or more independent tests or 2.0 SD below age-matched and
education-matched controls on one test between 2 neuropsycho-
logical test batteries performed in clinical practice or a research
study within 12 months prior to entry. Subjective criteria were
defined as cognitive decline noted by the participant, or a partic-
ipant’s family member, caregiver, or primary provider, and a
Center for Epidemiologic Studies Depression Scale (CES-D)
score 16 within 45 days prior to study entry. Participants were
excluded if they were 18 or 65 years of age, had an estimated
premorbid IQ 70 (as determined by the vocabulary section of
the Wechsler Adult Intelligence Scale–Revised [WAIS-R]), or
had a Karnofsky Functional Performance score 60. Partici-
pants also were excluded if they were pregnant or breast-feeding,
or had concurrent conditions including an active symptomatic
AIDS-defining opportunistic infection within 45 days prior to
entry, a current neoplasm, severe premorbid psychiatric illness,
confounding neurologic disorder, CNS infection, active drug or
alcohol use or dependence, or serious illness requiring systemic
treatment that in the opinion of the investigator would interfere
with the study requirements.
Standard protocol approvals, registrations, and patient
consents. The protocol was reviewed and approved by all ap-
propriate committees of the AIDS Clinical Trials Group
(ACTG) and the Institutional Review Boards at all participating
sites. The study is registered in clinicaltrials.gov (NCT
00361257). Informed consent was obtained from all participants
or their authorized representatives.
Randomization. At entry, stratified randomization was uti-
lized to assign treatment: minocycline 100 mg orally every 12
hours or matching placebo orally every 12 hours using permuted
blocks with a block size of 4. The randomization sequence for
each stratification combination was generated by the statistical
and data management center at the Harvard School of Public
Health and Frontier Science Technology Research Foundation.
Investigators at sites enrolled participants, and interventions
were assigned by site pharmacists. Two factors were used in the
stratification: detectable (30 RNA copies/mL) vs undetectable
(30 RNA copies/mL) CSF HIV viral load vs no lumbar punc-
ture, and progressive neurocognitive decline defined by objective
vs subjective criteria. HIV-1 RNA in CSF and plasma was mea-
sured using a reverse transcriptase PCR assay performed at the
University of Washington.17
Therapy and follow-up. Participants received the study drug
daily for 24 weeks during the double-blind phase. Participants
were re-evaluated at 2, 4, 8, 12, 18, and 24 weeks after random-
ization. At each visit, participants were assessed for adverse clini-
cal events. A neurologic examination and safety laboratory tests
including serum chemistry profiles, hematology, CD4
T-lymphocyte counts, and plasma HIV RNA levels were per-
formed at screening and weeks 4, 12, and 24. A neuropsycholog-
ical test battery was performed at screening, pre-entry, entry, and
at 12 and 24 weeks. The battery included the Hopkins Verbal
Learning Test Revised (HVLT-R), Trail Making Test parts A
and B,18 Grooved Pegboard Test with the dominant and non-
dominant hand,19 Symbol Digit Test,20 Timed Gait Test, Cali-
fornia Computerized Assessment Package (CALCAP), Choice
and Sequential Reaction Time Test,21 Stroop Color Interference
Task,22 and the International HIV Dementia Scale.23 Estimated
premorbid intellectual function was assessed with the WAIS-R vo-
cabulary subtest at screening. The presence of depression symptom-
atology was assessed with the CES-D24 at screening, entry, and
weeks 12 and 24. Functional performance was measured with the
Karnofsky Performance Score, the Instrumental Activities of Daily
Living, and the performance-based Modified Medication Manage-
ment Test25,26 at screening, entry, and weeks 12 and 24.
Outcome measures. The primary research question was to
evaluate the efficacy and safety for the treatment of HAND.
The primary measure of efficacy in this study was the change
in the composite neuropsychological z score (NPZ-8) from
baseline to week 24. The NPZ-8 was defined as the average of
z scores for the Trail Making Test parts A and B, Grooved
Pegboard Test with the dominant and nondominant hand,
CALCAP Choice and Sequential Reaction Time Test, Timed
Gait Test, and Symbol Digit Test. These specific tests were
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chosen because they are sensitive measures of HAND and
have been used in previous clinical trials for HAND.26 Sec-
ondary outcome measures of efficacy included the Global
Deficit Score,27,28 performance on individual neuropsycholog-
ical tests, changes in neuropsychological test z scores grouped
by cognitive domains, changes in individual subjective and
functional performance assessments, and changes in the In-
vestigator and Subject Clinical Global Impressions.26 Primary
measures of safety included the frequency of adverse events
and abnormal results on laboratory tests, and changes over
time in vital signs and laboratory tests.
Statistical methods. For the primary analysis, an intention-
to-treat analysis was conducted by first adopting a multiple im-
putation method to impute missing 24-week outcomes, and a
general linear model was fit to estimate the minocycline effect on
the 24-week change of NPZ-8. As a part of exploratory analyses,
we conducted an observed data analysis using a general linear
model, and also a longitudinal data analysis with a mixed model
utilizing the repeatedly measured NPZ-8 at weeks 12 and 24.
For the secondary analyses, no data were imputed and only the
observed data analyses were conducted. For continuous out-
comes, general linear models were used to estimate the minocy-
cline effect. For categorical outcomes, new dichotomous
variables were created (i.e., better vs no change/worse at 24
weeks compared to baseline), and logistic regressions were used
to estimate the effect.
Including both primary and secondary endpoints, 30 statistical
tests were conducted to examine the effect of minocycline compared
Figure Consort flow diagram of trial participation
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to placebo. Since Type I error of 0.10 was used for each test, it was
expected to observe 3 positive test results by chance.
Sample size was calculated to be 100, which provided 85%
power (  0.10) to detect a 0.5 difference of NPZ-8 changes
between groups assuming an SD of changes  0.7 adjusting for
17% loss to follow-up, 10% noncompliance, and potential need
for nonparametric testing (Mann-Whitney).
After 50% of the participants completed the double-blind
phase, an interim analysis of primary and secondary outcome
measures was performed. The results were reviewed by the Neu-
rologic AIDS Research Consortium Data Safety and Monitoring
Board on November 6, 2009, and they recommended early ter-
mination of the study, and participants returned for the final
study visits.
RESULTS Baseline characteristics. Among the 107
HIV-infected individuals with cognitive impairment
enrolled, 55 were randomized to placebo, and 52
were randomized to minocycline 100 mg every 12
hours. Eleven percent of the participants entered the
study with objective neuropsychological test decline,
and the remaining 89% entered the study with sub-
jective criteria for neurocognitive decline. The 2
treatment groups were similar with respect to demo-
graphics (table 1). The mean age for the participants
enrolled was 51 years, 83% were male, and 50% were
white. Previous IV drug use was reported by 23% of
the participants. The mean CD4 lymphocyte count
was 543 cells/mm3. The participants, all on a stable
antiretroviral regimen for at least 16 weeks prior to
study entry, predominantly exhibited well-controlled
viral replication with 86% of study participants hav-
ing an undetectable plasma HIV RNA 30 copies/
mL, and 93% (among those participants with
available CSF HIV RNA data) having an undetect-
able CSF HIV RNA 30 copies/mL. Most partici-
pants remained on the same antiretroviral regimen
with the exception of 17 participants in the placebo
group and 14 participants in the minocycline group
who changed antiretroviral therapy during the study
period.
At enrollment, 51% of the participants were
judged to have asymptomatic/subclinical cognitive
impairment (AIDS Dementia Complex [ADC])
stage 0.5, whereas 38% had mild dementia (ADC
stage 1), and 7% had moderate dementia (ADC stage
2).29 The baseline neuropsychological test z scores
(table 2) were similar across the 2 groups except for
Grooved Pegboard Test (dominant and nondomi-
nant hand tests), where participants in the placebo
group had a trend for a more impaired z score com-
pared to the minocycline group for both the domi-
nant hand test (placebo mean z score  0.72,
minocycline mean z score  0.33) and the non-
dominant hand test (placebo mean z score  0.74,
minocycline mean z score  0.37).
Efficacy. The changes from baseline to week 24 for
the primary outcome measure (NPZ-8) and individ-
ual neuropsychological test secondary outcome mea-
sures are reported in table 3. The minocycline
treatment group did not show improvement in the
primary outcome measure (NPZ-8) (mean 24-week
change in NPZ-8 score  0.12) compared with the
placebo group (mean 24-week change in NPZ-8
score  0.17) (95% confidence interval 0.26,
0.39, p  0.70). None of the secondary cognitive
outcome measures showed a difference between the 2
treatment groups with one exception. The 24-week
change in the Grooved Pegboard dominant hand z
score in a general linear model adjusting for baseline
neuropsychological test score and HAART CNS
penetration effectiveness score30 showed a benefit for
the minocycline group (mean 24-week z score
change  0.46) compared to the placebo group
(mean 24-week z score change  0.08); the minocy-
cline effect was estimated to be 0.505, 95% confi-








Age, y, mean (SD) 52 (7) 50 (7) 51 (7)
Years of education, mean (SD) 14 (3) 14 (3) 14 (3)
Male, n (%) 42 (76) 47 (90) 89 (83)
Race/ethnicity, n (%)
White non-Hispanic 28 (51) 26 (50) 54 (50)
Black non-Hispanic 21 (38) 24 (46) 45 (42)
Hispanic (regardless of race) 5 (9) 2 (4) 7 (7)
American Indian, Alaskan Native 1 (2) 0 (0) 1 (1)
Previous IV drug history, n (%) 13 (24) 12 (23) 25 (23)
Hepatitis C status, n (%)
Positive 14 (26) 10 (20) 24 (23)
Negative 38 (72) 41 (80) 79 (76)
Indeterminate 1 (2) 0 (0) 1 (1)
CD4 count, mean (SD) 535 (253) 552 (313) 543 (283)
Nadir CD4 count, mean (SD) 274 (259) 267 (254) 270 (254)
Plasma HIV RNA, <30 copies/mL, n (%) 41 (87) 42 (86) 83 (86)
CSF HIV RNA, <30 copies/mL, n (%)a 18 (90) 20 (95) 38 (93)
CES-D scale score, mean (SD) 10.43 (6.33) 11.54 (8.07) 10.96 (7.21)
IHDS, total score, mean (SD) 9.53 (1.90) 9.52 (1.75) 9.52 (1.82)
ADC stage, n (%)
Normal 0 (0) 4 (8) 4 (4)
Asymptomatic/subclinical 25 (46) 29 (57) 54 (51)
Mild 25 (46) 15 (29) 40 (38)
Moderate 4 (7) 3 (6) 7 (7)
Subjective neurocognitive decline, n (%) 48 (87) 47 (90) 95 (89)
Abbreviations: ADC  AIDS Dementia Complex; CES-D  Center for Epidemiologic Studies
Depression Scale; IHDS  International HIV Dementia Scale.
a Among those participants with available CSF HIV RNA data (n  41).
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dence interval 0.094, 0.915, p  0.017). However,
after adjusting for multiple comparisons, the result
was no longer significant. Also, no benefit for the
minocycline group was seen with the Grooved Peg-
board nondominant hand 24-week z score change
(data not shown). Differences were not detected in
the Global Deficit Score between the 2 treatment
groups. The results from the observed data and lon-
gitudinal data analyses also showed that the minocy-
cline effect was not different from the placebo effect.
No differences between the minocycline and
placebo groups were seen on the subject and inves-
tigator clinical global impressions, subjective and
performance-based functional measures, assessments
of mood (CES-D score), CD4 count, and viral
load assessments. There was no correlation be-
tween either the CES-D score or CD4 count and
individual neuropsychological tests. Of note, 2
participants in the minocycline group changed
from an undetectable plasma HIV RNA at base-
line to a detectable HIV RNA at 24 weeks. In
addition, 2 participants in the placebo group
changed from a detectable HIV RNA at baseline
to an undetectable HIV RNA at 24 weeks.
Safety. There were no deaths reported in the study.
In the placebo group, severe adverse events included
general body pain (n  2), fever (n  1), headache
(n  1), cough (n  1), vomiting (n  1), and
depression (n  1). In the minocycline group, severe
adverse events included tooth discoloration (n  1)
and mental status changes with suicidal ideation
(n  1). Twenty-five participants in the placebo
group and 20 participants in the minocycline group
had laboratory abnormalities. Life-threatening (grade
4) laboratory abnormalities were seen in no partici-
pants in the placebo group and one participant in the
minocycline group (increased amylase). Severe (grade
3) laboratory abnormalities observed in the placebo
group included changes in phosphorus (n  6), fasting
glucose (n  1), absolute neutrophil count (n  1), and
lipase (n  1). Severe laboratory abnormalities observed
in the minocycline group included changes in phos-
phorus (n  2), albumin (n  1), nonfasting glucose
(n  1), total bilirubin (n  1), and creatinine (n 
1). Mild to moderate hyperpigmentation, a known
side effect from any tetracycline, was noted in 10
patients, with severe hyperpigmentation (tooth dis-
coloration) seen in one patient on minocycline.








HVLT-R: learning z 1.35 (1.10) 1.27 (1.17) 1.32 (1.13)
HVLT-R: delay z 1.46 (1.25) 1.40 (1.26) 1.43 (1.25)
HVLT-R: % retained z 0.83 (1.38) 0.88 (1.33) 0.86 (1.35)
HVLT-R: recognition discrimination z 1.08 (1.40) 0.97 (1.35) 1.03 (1.37)
Stroop Color Naming z 1.03 (1.55) 0.87 (1.17) 0.95 (1.37)
Stroop Word Reading z 1.78 (3.17) 1.16 (1.35) 1.48 (2.48)
Stroop Interference Trial z 0.39 (1.24) 0.35 (1.02) 0.37 (1.13)
Basic Choice Reaction Time z 1.50 (2.11) 1.51 (2.20) 1.50 (2.14)
Sequential Reaction Time z 0.56 (1.21) 0.60 (1.11) 0.58 (1.16)
Symbol Digit z 1.24 (1.18) 1.11 (1.15) 1.18 (1.16)
Grooved Pegboard–dominant z 0.72 (1.01) 0.33 (1.04) 0.53 (1.04)
Grooved Pegboard–nondominant z 0.74 (1.12) 0.37 (1.04) 0.56 (1.09)
Trail Making A z 0.02 (1.09) 0.04 (1.02) 0.01 (1.05)
Trail Making B z 0.11 (1.22) 0.26 (1.26) 0.18 (1.24)
Timed gait: average z 3.66 (4.16) 2.44 (3.10) 3.06 (3.71)
NPZ-8 1.03 (0.98) 0.75 (0.90) 0.90 (0.95)
Abbreviations: HVLT-R  Hopkins Verbal Learning Test Revised; NPZ-8  neuropsycholog-
ical z score.











Timed Gait change 0.08 (2.68) 0.22 (1.61) 0.15 (2.20) 0.35, 1.36 0.244
Grooved Pegboard Dominant change 0.08 (0.75) 0.46 (1.19) 0.25 (0.99) 0.09, 0.92 0.017
Grooved Pegboard nondominant change 0.03 (0.77) 0.08 (0.76) 0.05 (0.76) 0.18, 0.44 0.416
Trail Making A change 0.17 (1.12) 0.09 (0.84) 0.13 (1.00) 0.47, 0.28 0.613
Trail Making B change 0.13 (0.97) 0.06 (0.83) 0.10 (0.91) 0.40, 0.26 0.679
Symbol Digit change 0.07 (0.92) 0.15 (0.76) 0.11 (0.85) 0.45, 0.28 0.637
Basic Choice Reaction Time change 0.23 (1.66) 0.04 (2.60) 0.14 (2.14) 0.85, 0.54 0.663
Sequential Reaction Time change 0.18 (1.02) 0.24 (0.95) 0.21 (0.98) 0.36, 0.39 0.938
NPZ-8 changes 0.17 (0.67) 0.12 (0.71) 0.15 (0.69) 0.26, 039 0.651
Abbreviation: NPZ-8  neuropsychological z score.
a Adjusted for baseline neuropsychological test score and highly active antiretroviral therapy CNS penetration score.
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DISCUSSION In this study, minocycline was safe
and well-tolerated in individuals with HIV-
associated cognitive impairment. Overall, there were
few severe adverse events or laboratory abnormalities
in either treatment group, and there were no deaths
reported. No differences were detected in the pri-
mary outcome measure, the NPZ-8, among partici-
pants receiving minocycline compared to placebo.
Similarly, no differences were detected among the 2
groups in the change scores for almost all of second-
ary outcome measures of cognitive performance with
one exception, the Grooved Pegboard dominant
hand. Differences in change scores in functional per-
formance were not detected among the minocycline
or placebo groups.
HIV individuals with progressive cognitive
impairment defined by either subjective or objec-
tive criteria were recruited for this study. It was
hypothesized that individuals with HAND who
had progressive cognitive impairment were most
likely to have active CNS inflammation due to
HIV and thus most likely to obtain a therapeutic
benefit from minocycline.
We required individuals to be on a stable antiret-
roviral regimen at entry so as not to confound any
effects from minocycline with those that might result
from changes in antiretroviral therapy. The propor-
tion of study participants on antiretroviral therapy
with active viral replication was low, with 86% of
participants having an undetectable plasma HIV
RNA and 93% of participants having an undetect-
able CSF HIV RNA. Thus, there are insufficient
data to determine whether minocycline treatment
might have a direct effect on inhibiting HIV replica-
tion as suggested by in vitro data in cultured macro-
phages and lymphocytes.14,15
There are a number of potential explanations for
why this study failed to demonstrate a clinical benefit
for minocycline. The treatment period of 24 weeks
may have been too short to produce a neuroprotec-
tive effect. In part, the cognitive impairment in our
study participants may have been due to non-HIV
comorbid conditions such as hepatitis C coinfection
or other comorbid conditions such as remote effects
from illicit drug or alcohol use, depression, or side
effects from medications. Minocycline at the dose
used may have had inadequate penetration within
the CNS, although among antibiotics, minocycline
has relatively good brain penetration.31,32 HIV enters
the CNS shortly after infection and may cause neu-
ronal injury or dysfunction that after treatment with
antiretroviral therapy is unresponsive to potential
anti-inflammatory or neuroprotective effects from
minocycline. Surrogate markers such as neuroimag-
ing (e.g., magnetic resonance spectroscopy) or CSF
biomarkers may be needed to evaluate early evidence
of neuroprotection within the CNS rather than the
clinical neuropsychological tests and functional out-
comes used in this evaluation.
Minocycline has been shown to have a neuropro-
tective effect in animal models of other neurologic
conditions such as multiple sclerosis (MS),33,34 Par-
kinson disease,11 Huntington disease,35,36 amyotro-
phic lateral sclerosis (ALS),36,37 and traumatic brain
disease.10,38 In some of these conditions, minocycline
has had a therapeutic benefit in clinical trials. In a
small open-label study of 10 individuals with
relapsing-remitting MS, minocycline decreased MRI
activity as measured by the number of gadolinium-
enhancing MRI lesions.39 Also, in an acute ischemic
stroke study of 152 patients, participants receiving
minocycline treatment had better outcomes on the
NIH Stroke Scale, a modified Rankin Scale, and the
Barthel Index over a 90-day period compared to par-
ticipants receiving placebo.6 However, in a study of
412 individuals with ALS, participants on minocy-
cline had faster deterioration on an ALS functional
rating scale measuring gross and fine motor tasks,
bulbar function, and respiratory function compared
to those receiving placebo.40
The reason for the discrepancy between the mino-
cycline effects in the SIV encephalitis model and
those in HIV individuals is unclear. Further stud-
ies are needed to define the precise anti-
inflammatory and neuroprotective properties of
minocycline in the SIV encephalitis model. Although
this study failed to demonstrate a beneficial impact of
minocycline on HAND, additional studies using
more sensitive markers of neurologic change may of-
fer better opportunities to further assess minocycline
as a potential anti-inflammatory and neuropro-
tectant treatment for CNS conditions associated
with inflammation such as HAND, MS, and acute
stroke.
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